Coronavirus Pandemic

Evaluation of sample pooling for gene sequencing of SARS-CoV-2: a simulation study

Heng Chen^{1,2 #}, Yue Cheng^{1,2 #}, Xun He^{1,2}, Yuzhen Zhou^{1,2}, Wenjun Xie^{1,2}, Danyun Shen^{1,2}, Zhiqun He², Ruidan Li², Weixuan Liu², Liang Wang^{1,2}, Xuejun Zhang³

¹ Chengdu Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences, Chengdu, 610047, China

² Chengdu Center for Disease Control and Prevention, Chengdu, 610047, China

³ Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, 610066, China

Authors contributed equally to this work.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) continues to pose a significant public health threat, requiring epidemiological and genomic surveillance. Next generation sequencing (NGS) is commonly utilized for monitoring viral evolution at a high cost. This study evaluated pooled sequencing as a cost-effective tool for monitoring virus variants.

Methodology: A simulation study was conducted to evaluate the efficacy of sample pooling for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing. In total, 72 original sets of raw data of gene sequencing with different genotypes were collected and combined to create 70 simulated samples based on five pooling strategies. A bioinformatics tool based on Freyja was utilized to analyze the variant composition of these 70 simulated pooled samples. The efficiency of recovering the correct genotypes of the original samples among different pooling strategies, result reports, and genotypes was evaluated with R software.

Results: The genetic composition of the pooled samples mostly recovered the genotype compositions of the original samples, with discrepancies between the top X results (where X is the number of original samples in the pool) and the complete results (p < 0.05). Variability in identification efficiency of genotypes were observed in the reports for the top X results (p < 0.05) across the five pooling strategies, but not in the reports of complete results (p > 0.05). Some original samples of low quality were not accurately identified.

Conclusions: Sample pooling coupled with streamlined genotyping offers a promising approach for cost-effective gene sequencing of SARS-CoV-2, which will aid in COVID-19 genomic surveillance.

Key words: SARS-CoV-2; sample pooling; gene sequencing; simulation study.

J Infect Dev Ctries 2025; 19(1):1-8. doi:10.3855/jidc.20348

(Received 23 May 2024 - Accepted 16 October 2024)

Copyright © 2025 Chen *et al.* This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

The impact of the coronavirus disease 2019 (COVID-19) pandemic on both human health and the social economy has been profound. The World Health Organization (WHO) conducted a study between 22 July to 18 August 2024 to estimate the impact of COVID-19 and reported that over 776 million confirmed cases and more than seven million deaths have been reported globally since the beginning of the pandemic [1]. The rapid mutation rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the emergence and global dissemination of new variants with distinct phenotypes in transmissibility, severity, and immune evasion [2]. Fourteen months after the World Health Organization (WHO) declared an end to the public health emergency of international concern regarding COVID-19, there were over 238,000 new cases reported across 91 (39%) countries, and about 4,400 new fatalities reported across 35 (15%) countries during the 28-day period (from July 22, to August 18, 2024), primarily attributed to the prevalence of the lineages of JN.1 and the variant KP.3.1.1 [1]. Ongoing genomic surveillance remains crucial for addressing the persistent threat of new variants and outbreaks due to the continuous evolution and spread of the SARS-CoV-2 virus [3]. In the post-pandemic era, the focus of genome sequencing has shifted from individual diagnosis and molecular epidemiology tracing; to the surveillance of population spread, and the genetic diversity and evolution of SARS-CoV-2 within communities. The viral genotypes and their compositions in populations can be used to track the emergence of new variants and genetic changes, which

is of significant importance for early warning and risk assessment of COVID-19.

Next generation sequencing (NGS) is widely used to monitor viral evolution. Notably, the sequences of SARS-CoV-2 shared on GISAID (https://gisaid.org/) vary significantly across continents, with Europe contributing the most and Africa the least (even lower than Oceania). Cost and sequencing throughput are likely limitations affecting the use of genomic surveillance in tracking the possible risk of COVID-19. These factors can influence our understanding of the prevalence of variants of concern or interest (VOCs/VOIs). A high-throughput, low-cost sequencing method will offer notable advantages and be valuable for public health.

During the COVID-19 epidemic, the practice of pooling SARS-CoV-2 samples was utilized for population screening due to its recognized benefits [4-5]. Pooling samples increase the throughput of molecular testing and reduce costs [6], making them an economically advantageous option. However, the challenge lies in the results analysis of pooled sequencing, specifically in accurately estimating the composition of multiple SARS-CoV-2 lineages within samples containing mixed viral populations. A bioinformatics analysis method using Freyja has revolutionized the challenges of analyzing mixed sequencing data and has been applied in the sequencing of sewage (mixed) samples for SARS-CoV-2 [7], indicating the potential for population-based pooled sequencing. Pooled sequencing presents a cost-efficient approach for acquiring sufficient genomic data in areas with constrained sequencing capabilities and high demand, thereby enriching our understanding of viral evolutionary and transmission patterns.

This study aimed to assess the efficacy of lineage classification for SARS-CoV-2 in various simulated pooling samples. The objective was to evaluate the potential of pooled sequencing as a genomic surveillance tool for COVID-19.

Methodology

Original samples

The original raw data (in fastq.gz format) from gene sequencing procedures carried out using Illumina NGS platforms (Illumina, USA) were collected in our laboratory between 2020 and 2024. This dataset included samples from individuals and vaccine materials (CoronaVac, the Sinovac inactivated SARS-CoV-2 vaccine). A coverage exceeding 96% was the fundamental criterion for inclusion of effective sequences in our country; while a depth surpassing $1000 \times$ was determined by the average sequence depth acquired in our laboratory. It was observed that data with depths below this threshold were generally of low quality. Subsequently, samples meeting our criteria (minimum 96% coverage and depth exceeding $1000 \times$ for the entire genome of SARS-CoV-2) were identified as genotype-determined specimens. In addition, to test the impact of low-quality sequencing samples on the results, data from two low-quality sequencing samples were randomly included.

The study established various genotype groups at different hierarchical levels: 4 in the first-level classification including the groups of Original*, BA*, XBB*, and recombinants; six in the second-level classification by dividing the genotypes of BA*and XBB* into four subgroups (BA.1 + BA.5, BA.2, XBB.1.9*, and XBB* without XBB.1.9*), and 38 of subdivided subtypes in the third-level classification. A total of 72 samples representing all the available subtypes in our laboratory were included in the study (Supplementary Table 1). A total of 500,000 raw data reads were randomly extracted for each sample using the subsample tool of CLC Workbench 23.0 software (Qiagen, Dusseldorf, Germany) to create original samples.

Pooling strategy design

Potential interactions among genotypes of SARS-CoV-2 in real-world scenarios by integrating genotype classification and historical prevalence of the virus were assessed, and 5 distinct pooling strategies were developed. Five groups of mixtures were created to simulate sample pooling for gene sequencing using the Create Sequence tool within the CLC Workbench 23.0 software (Qiagen, Düsseldorf, Germany). The details of the simulated samples and mixtures are listed below and presented in Table 1.

1) A mixture of 5 groups was formed based on the second-level classification, excluding "recombinants". One random sample from each group was selected and mixed equally, labeled as "mix."

2) The samples were classified into 3 specific groups based on the first-level classification, excluding "recombinants". A mixture of transition between 2 groups, comprised of movement from the original* stage to the BA* stage, and from the BA* stage to the XBB* stage. Random samples were selected from each of the 2 groups at varying ratios of 1:4, 3:2, and 4:1, respectively; and combined as a mixture labeled as "change."

3) The samples were classified into three specific groups based on the first-level classification, excluding

"recombinants". Five random samples were selected from each group and combined, then labeled as "genotype-class I".

4) The samples were grouped into 8 categories based on prevalent lineages, with Delta\XBB.1.5\XBB.1.9.1\XBB.1.9.2\XBB.1.16\BA.5 .2\BA.5.2.48&49\JN being the most common. Each group was combined to create one simulated sample labeled as "genotype-class II".

5) Three recombinants of XBF/XBL/XBC, along with 3 simulated recombinants of XBG/XBC/XDD; in total 6 recombinants based on the third-level classification; were identified and labeled as "recombinants".

Data analysis

The combined data from simulated samples underwent genotype and abundance analysis using the bioinformatics software module within the Pathogenic Microbial Analysis System (V1.0.6, MicroFuture, Beijing, China). Specifically, the analysis was conducted utilizing the SARS-CoV-2 Analysis Module for Environmental Samples of the software. This system is underpinned by the Freyja algorithm and makes use of the genotyping tool Nextclade (https://clades.nextstrain.org/).

The study assessed the lineage abundances, ranked genotype composition by abundance, and examined the genetic consistency between simulated pooled samples and the original samples. The consistency assessment was mainly based on the "genotype of original samples"

Table 1. Pooling strategy for mixture as simulated samples.

(Table 1). This evaluation was conducted based on the top X results (X representing the number of original samples in the mixture) and the complete results.

The efficiency of recovering the correct genotypes of the original samples using different pooling strategies, result reports, and genotypes was evaluated with R software (http://www.R-project.org, version 4.2.1). The categorical variables were analyzed using either the Chi square test or Fisher's exact probability method (when there were expected frequencies below 5 in the 2×C table) to compare the differences in gene identification efficiency among different hybridization strategies and result reports. Statistical significance was defined as a *p* value < 0.05.

Results

General identification efficiency of pooled sequencing

This study included 72 original samples and 70 simulated pooled samples (details in Supplementary Table 2). Among these, 39 simulated samples precisely matched the original genotypic compositions (good), while 24 samples had one missing genotype (mediocre), and 7 samples had two missing genotypes (bad); as determined by the top X results. In contrast, 61 simulated samples exactly replicated the genetic compositions of the original samples, with 9 samples containing one missing genotype as determined by the complete results. There were no "bad" results observed in the entire output. The complete results demonstrated superior identification compared to the top X results across all pooling strategies. Among the various

Group	Classification	Pooling strategy for mixture	Counts of simulated samples
Mix	Second level	1 out of each 5 groups randomly (excluding recombinants group)	5
Change	First level	Original (1):BA*(4)	5
		Original (3):BA*(2)	5
		Original (4):BA*(1)	5
		BA*(1):XBB*(4)	5
		BA*(3):XBB*(2)	5
		BA*(4):XBB*(1)	5
Genotype-Class I	First level	5 out of the group of Original randomly	5
		5 out of the group of BA* randomly	5
		5 out of the group of XBB* randomly	5
Genotype-Class II	Third level	all the samples of Delta* group	1
		all the samples of XBB.1.5* group	1
		all the samples of XBB.1.9.1* group	1
		all the samples of XBB.1.9.2* group	1
		all the samples of XBB.1.16* group	1
		all the samples of JN* group	1
		all the samples of BA.5.2* group	1
		all the samples of BA.5.2.48/49* group	1
Recombinants	Third level	XBF	1
		XBL.3	1
		XBC.1.6.2, XBG#, Omicron (BA.2.76)*1 + Omicron (BA.5.2)*3	3
		XBC#, Omicron (BA.2) *1, + Delta (B.1.617.2*)*3	3
		XDD#, Omicron (EG.5.1.1) *1 + Omicron (JN*)*3	3
Total			70

*: including the lineage and its subtypes.

Variable	Consistency												
variable	Ν	Identified (N)	Identified (%)	Unidentified (N)	Unidentified (%)	p value							
Result-rank													
Тор Х	70	39	55.71	31	44.29	< 0.001#							
Complete	70	61	87.14	9	12.86	$(\chi^2 = 16.94)$							
Pooling strategy-top X													
Mix	5	0	0.00	5	100.00	0.003*							
Change	30	15	50.00	15	50.00								
Genotype-class i	15	7	46.67	8	53.33								
Genotype-class ii	8	6	75.00	2	25.00								
Recombinant	12	11	91.67	1	8.33								
Pooling strategy-complete													
Mix	5	3	60.00	2	40.00	0.256*							
Change	30	26	86.67	4	13.33								
Genotype-class i	15	13	86.67	2	13.33								
Genotype-class ii	8	7	87.50	1	12.50								
Recombinant	12	12	100.00	0	0.00								

Table 2. Consistency of simulated pooling samples and original samples among various pooling strategies.

#, Pearson's Chi-squared test; *, Fisher's exact test.

pooling strategies, the "mix" group consisting of five original samples with completely different genotypes exhibited the poorest identification, while the "recombinants" group with one or two original samples displayed the highest level of identification. The blending of closely related genotypes within groups such as "genotype-class I" and "genotype-class II" yielded approximately average identification results, with over 80% distinguishable outcomes as indicated by the complete results, along with the remaining group of "change". The genetic compositions of the simulated pooling samples largely reflected the correct variant proportions of the original samples, with variability observed across different pooling strategies, as depicted in Figure 1.

Identification efficiency among different pooling strategies and result reports

By categorizing consistent results as identified and missing results as unidentified, the statistical analysis revealed significant differences in the top X and complete reports, with a Chi square value of 16.94 (p <0.001). The complete results revealed a higher percentage of identified samples (87.14%) compared to the top X results (55.71%). While there was variability in the top X result reports among the five groups (p =

bad
mediocre

good



Pooling strategy

The identification of original genotypes by different pooling strategies in the proportions of the original subtypes by the top X results and complete results, respectively. Gray color represents bad with two genotypes missing, orange represents mediocre with one genotype missing, and blue represents good with no genotype missing.

0.003, < 0.05), the complete reports showed no significant differences in the pooling strategies employed (p = 0.256, > 0.05). Analysis of the top X results indicated that the "mix" group did not accurately recover the genetic compositions of original samples, but successfully identified the majority of samples (91.67%) within the "recombinants" group. Overall, the identification accuracy improved in the complete results across all pooling strategies compared to the top X results (Table 2).

Identification efficiency among different genotypes

Regarding specific genotypes, the majority of original samples were accurately identified within mixed samples based on both the top X results and complete results. The complete results also successfully identified some previously unidentified genotypes from the top X results. However, a few original samples were not correctly identified in either the top X results or the complete results. Examples include B.1.1.48 (mistaken for B.1.551 or missing), BA.2.76 (not consistently detected in most simulated samples), and XBB.1.16.2.1.1 (identified XBB.1.16.2 as or XBB.1.16.2.1). This is illustrated in Figure 2. It is important to note that a majority of the unidentified pooled samples contained low-sequencing-quality original samples, as mentioned above.

Discussion

Continuous monitoring and tracking of the mutations and variants of SARS-CoV-2 is crucial for risk assessment and early epidemic warning; and the cost-effective pooled sequencing strategy may facilitate

progress in this endeavor. Unlike qualitative pooling tests, in real time quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), pooled sequencing necessitates a more intricate analysis involving mutation definition, lineage identification, and quantitative assessment of each lineage. Existing tools for SARS-CoV-2 lineage classification, such as Phylogenetic Assignment of Named Global Outbreak LINeages (Pangolin) or Ultrafast Sample Placement on Existing Trees (UShER), are primarily designed for clinical samples dominated by a single variant [8,9]. In the case of pooled samples, the complexity has been addressed through the development of the Freyja approach. The bioinformatics analysis tool was utilized to estimate the relative frequencies of SARS-CoV-2 variants, employing a statistical model that incorporates a predefined set of genomic polymorphisms specific to these variants [7]. In other words, Freyja uses a "barcode" library of lineage-defining mutations to represent each lineage in the global phylogen for SARS-CoV-2, and then restores relative lineage abundance by solving the depth-weighted least absolute deviation regression problem. This approach has demonstrated efficacy in monitoring sewage samples across several countries [10,11]. In 2023, we successfully applied the Freyja tool in urban sewage monitoring, and obtained information of the genomic composition and abundance for SARS-CoV-2. In this study, the patient swab samples had higher viral loads and were less diluted compared to wastewater samples. The software based on Freyja effectively identified the correct variant proportions in the majority of simulated samples. In fact, this tool also provided a

Figure 2. The identification of original genotypes among different genotypes.



The numbers of unidentified samples of different original genotypes by the top X results and complete results, respectively in gray and blue.

comprehensive list of all mutations present which was useful for genomic monitoring (not shown in this study). Moreover, as an innovative bioinformatics analysis approach, Freyja has been incorporated into diverse software tools for pooled sequencing of SARS-CoV-2, and it is also compatible for self-analysis using R software. Nonetheless, there are notable considerations regarding the implementation of pooled sequencing in genomic surveillance that warrant further attention.

Not all simulated samples were accurately recovered, primarily due to original samples lacking definitive mutations and exhibiting lower recognition quality. For instance, the simulated samples harboring B.1.1.48 (assessed as low-quality by Nextclade) and BA.2.76 (with less than 96% coverage) led to 36.8% unidentified cases among the top X results and 80% among complete results. Therefore, ensuring the sequencing quality of original samples before pooling is essential, because samples of poor quality can compromise identification accuracy. High-quality nucleic acid, characterized by both high concentration and purity, plays a key role in achieving superior sequencing outcomes, yet ensuring this may be challenging due to various factors that come into play during the sequencing process. However, the assessment of sequencing quality in the absence of sequence testing for the original samples raises questions regarding the feasibility of using cycle threshold (Ct), DNA integrity number (DIN), or RNA integrity number (RIN) values as indicators alone. Further investigation is required to establish quality control measures prior to pooling. We are trying to assess the quality of the library construction process to derive evaluation parameters that are more pertinent to sequencing quality, thereby enhancing the accuracy of sample selection in pooled sequencing.

Additionally, observations indicated that samples with lower viral loads could be overlooked in the final pooled RT-qPCR result [12], emphasizing the importance of pooling samples with high and similar nucleic acid concentrations. In simulated experiments, each sample is mixed with an equal number of reads, but the situation may vary in actual detection. Drawing from our experience in routine sequencing, adjustments in the proportion of labeled samples can be made based on the concentration of nucleic acids or libraries to ensure balanced data acquisition from each sample. Therefore, volume adjustments in pooled sequencing can also be tailored according to the nucleic acid concentration of original samples to achieve a more uniform mixing, optimizing abundance balance, and reducing the likelihood of missed detection due to low data yield. When multiple original samples in a pooled sample share the same genotype, they become indistinguishable in pooled sequencing. Notably, adherence to the principle of approximately equal mixing may result in higher abundance, indicating a greater composite representation. Moving forward, the development of mathematical models could aid in mitigating such interference in pooled sequencing.

We also detected some unexpected variant sites. This may be either a misjudgment or the result of amplifying low-frequency variants in each sample due to an enrichment effect. This could serve as a meaningful early warning for exploring variants, warranting further investigation.

The software utilized for analyzing genomic composition ranked the abundance results, revealing differences between the top X results and the complete results. Upon simulating various pooling scenarios, statistical discrepancies were noted among the different pooling strategies, particularly when focusing on the top X results. Optimal consistency between the simulated samples and original samples was observed in the "recombinants" group, while the "mix" group showed the lowest level of consistency. These findings suggest that the complexity of the pooled samples significantly affects the accuracy of identification as well.

While the complete results demonstrated improved identification compared to the top X results, there were instances of inaccurate genotyping due to the presence of low-abundance mutation mixtures. The Freyja method incorporated a bootstrap technique to calculate standard errors for predicting variant compositions. However, determining the optimal cutoff value for genomic composition results that strike a balance between sensitivity and specificity remained a challenge. An additional constraint is that pooled sequencing can only determine the viral genotype compositions and abundance, necessitating individual identification when new variants emerge, similar to individual confirmation in pooling tests for RT-qPCR [13].

The study commenced by sporadically conducting gene sequencing on a pooled sample of routine tests, and successfully recovered most of the genotypes present in the individual samples (Supplementary Table S3). Due to the impracticality of pooling numerous samples into diverse groups, a simulated study was conducted to assess the feasibility of pooled sequencing. The pooling strategy designed based on historical data aligned well with the real world and

recent data also confirmed this. The monitoring of genomic diversity in the population in Chengdu in 2023 showed distinct phases throughout the year. Initially, the prevalent strains were BA.5.2.48, which gradually declined by week 19. Subsequently, a combination of major stains XBB.1.5, XBB.1.9.1, and XBB.1.9.2 were observed between the 12th and the 27th week. From the 27th week onwards, XBB.1.9.2 emerged as the predominant strain. This was similar to the pooling strategy of "change". Since 2024, the dominant genotypes have consistently been the JN lineage and XDV recombinants. The patterns of genotype mixing resembled the strategic pooling of "genotype-class II", "recombinant", and "change". If the one-in-five mixed sampling was implemented in practice, it would result in a potential cost saving of around 80%, making it a highly cost-effective approach to monitoring.

Existing models for pooling tests in RT-qPCR wastewater-based epidemiological [14,15] and offer valuable insights for monitoring [16] implementing pooled sequencing for SARS-CoV-2. However, additional details are necessary for practical application, including the pooling procedure, pooling size, influencing factors, quality control of original samples, and optimization strategies of bioinformatics software. The rapid variation of the SARS-CoV-2 continually pose risks of new variants emerging and subsequent outbreaks. The presence of post-acute sequelae of SARS-CoV-2 (PASC) and incomplete understanding of the virus may cause more health hazards than common respiratory diseases such as influenza. Although the public attention towards COVID-19 has waned, it remains a virus requiring vigilance, as evidenced by the monthly updates from GISAID and reports from the WHO. Regular population surveillance remains an ongoing standard practice for the sake of public health. Timely awareness of virus variants and trends in their prevalence plays a constructive role in making prompt public health decisions, such as vaccine development, drug stockpiling, allocation of medical resources, and adjustments in prevention and control policies.

Pooled sequencing is recommended for population monitoring to approximate virus genotypes and their compositions, as the primary objectives. The approach aims to monitor virus variations, determine population prevalence, shift the focus from individuals to the overall population, and offers efficiency and cost advantages in this context. Nevertheless, for detailed genotypic analysis of SARS-CoV-2 or advanced research purposes, the traditional single sequencing methods remains indispensable.

Conclusions

This study utilized simulated mixed samples to assess the feasibility of pooled sequencing with analysis using the Freyja tool. The findings demonstrated the successful recovery of the gene composition of the original samples. Therefore, pooled sequencing presents itself as a promising tool that can enhance genomic surveillance efforts in combating COVID-19 in a cost-effective manner.

Acknowledgements

We are sincerely grateful to the colleagues involved in the epidemiological investigation, sampling, laboratory testing, and data analysis; as well as the patients who consented to donate their swab samples for detection. Special thanks to Professor Xiang Zhao (Chinese Center for Disease Control and Prevention) for helpful comments and assistance in designing the methodology for the study.

Authors' contributions

Conceptualization: HC, LW; methodology and software analysis: XZ, validation: HC; formal analysis: XZ; experiments, resources, and data curation: XH, YZ, WX, DS, ZH, RL, WL; writing – original draft: HC, YC; writing – review and editing: XZ, LW; supervision: LW; funding acquisition: XZ, HC, YC. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Assoc. Professor Xuejun Zhang, MD. Institute of Blood Transfusion Academy of Medical Sciences & Peking Union Medical College, No.26 Huacai Road, Longtan Industry Park, Chenghua District, Chengdu City, Sichuan Province, PR China. Tel: 86-28-61648518 Email: hotbird007@163.com

Conflict of interests: No conflict of interests is declared.

References

- World Health Organization (2024) COVID-19 epidemiological update – 17 September 2024. Available: https://www.who.int/publications/m/item/covid-19epidemiological-update-edition-171. Accessed: 17 September 2024.
- Flores-Vega VR, Monroy-Molina JV, Jiménez-Hernández LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R (2022) SARS-CoV-2: evolution and emergence of new viral variants. Viruses 14: 653. doi: 10.3390/v14040653.
- Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A (2023) The evolution of SARS-CoV-2. Nat Rev Microbiol 21: 361–379. doi: 10.1038/s41579-023-00878-2.
- Chong BW, Tran T, Druce J, Ballard SA, Simpson JA, Catton M (2020) Sample pooling is a viable strategy for SARS-CoV-2 detection in low-prevalence settings. Pathology 52: 796–800. doi: 10.1016/j.pathol.2020.09.005.

- Augenblick N, Kolstad J, Obermeyer Z, Wang A (2022) Pooled testing efficiency increases with test frequency. Proc Natl Acad Sci USA 119: e2105180119. doi: 10.1073/pnas.2105180119.
- Grobe N, Cherif A, Wang X, Dong Z, Kotanko P (2021) Sample pooling: burden or solution? Clin Microbiol Infect 27: 1212–1220. doi: 10.1016/j.cmi.2021.04.007.
- Karthikeyan S, Levy JI, De Hoff P, Humphrey G, Birmingham 7. A, Jepsen K, Farmer S, Tubb HM, Valles T, Tribelhorn CE, Tsai R, Aigner S, Sathe S, Moshiri N, Henson B, Mark AM, Hakim A, Baer NA, Barber T, Belda-Ferre P, Chacón M, Cheung W, Cresini ES, Eisner ER, Lastrella AL, Lawrence ES, Marotz CA, Ngo TT, Ostrander T, Plascencia A, Salido R A, Seaver P, Smoot EW, Mcdonald D, Neuhard RM, Scioscia AL, Satterlund AM, Simmons EH, Abelman DB, Brenner D, Bruner JC, Buckley A, Ellison M, Gattas J, Gonias SL, Hale M, Hawkins F, Ikeda L, Jhaveri H, Johnson T, Kellen V, Kremer B, Matthews G, Mclawhon RW, Ouillet P, Park D, Pradenas A, Reed S, Riggs L, Sanders A, Sollenberger B, Song A, White B, Winbush T, Aceves C M, Anderson C, Gangavarapu K, Hufbauer E, Kurzban E, Lee J, Matteson NL, Parker E, Perkins SA, Ramesh KS, Robles-Sikisaka R, Schwab MA, Spencer E, Wohl S, Nicholson L, Mchardy IH, Dimmock DP, Hobbs CA, Bakhtar O, Harding A, Mendoza A, Bolze A, Becker D, Cirulli ET, Isaksson M, Schiabor Barrett KM, Washington NL, Malone JD, Schafer AM, Gurfield N, Stous S, Fielding-Miller R, Garfein RS, Gaines T, Anderson C, Martin NK, Schooley R, Austin B, Maccannell DR, Kingsmore SF, Lee W, Shah S, Mcdonald E, Yu AT, Zeller M, Fisch KM, Longhurst C, Maysent P, Pride D, Khosla PK, Laurent LC, Yeo GW. Andersen KG. Knight R (2022). Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature 609: 101-108. doi: 10.1038/s41586-022-05049-6.
- Turakhia Y, Thornlow B, Hinrichs AS, De Maio N, Gozashti L, Lanfear R, Haussler D, Corbett-Detig R (2021) Ultrafast Sample placement on Existing tRees (UShER) enables realtime phylogenetics for the SARS-CoV-2 pandemic. Nat Genet 53: 809–816. doi: 10.1038/s41588-021-00862-7.
- 9. Rambaut A, Holmes EC, OToole Á, Hill V, McCrone JT, Ruis C, Plessis L, Pybus OG (2020) A dynamic nomenclature

proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 5: 1403–1407. doi: 10.1038/s41564-020-0770-5.

- Khan M, Li L, Haak L, Payen SH, Carine M, Adhikari K, Uppal T, Hartley PD, Vasquez-Gross H, Petereit J, Verma SC, Pagilla K (2023) Significance of wastewater surveillance in detecting the prevalence of SARS-CoV-2 variants and other respiratory viruses in the community - a multi-site evaluation. One Health 16: 100536. doi: 10.1016/j.onehlt.2023.100536.
- Reis AC, Pinto D, Monteiro S, Santos R, Martins JV, Sousa A, Páscoa R, Lourinho R, Cunha MV (2024) Systematic SARS-CoV-2 S-gene sequencing in wastewater samples enables early lineage detection and uncovers rare mutations in Portugal. Sci Total Environ 921: 170961. doi: 10.1016/j.scitotenv.2024.170961.
- Mulu A, Alemayehu DH, Alemu F, Tefera DA, Wolde S, Aseffa G, Seyoum T, Habtamu M, Abdissa A, Bayih AG, Beyene GT (2021) Evaluation of sample pooling for screening of SARS CoV-2. PLoS One 16: e0247767. doi: 10.1371/journal.pone.0247767.
- Hogan CA, Sahoo MK, Pinsky BA (2020) Sample pooling as a strategy to detect community transmission of SARS-CoV-2. JAMA 323: 1967–1969. doi: 10.1001/jama.2020.5445.
- Hanel R, Thurner S (2020) Boosting test-efficiency by pooled testing for SARS-CoV-2-Formula for optimal pool size. PLoS One 15: e0240652. doi: 10.1371/journal.pone.0240652.
- Perchetti GA, Sullivan KW, Pepper G, Huang ML, Breit N, Mathias P, Jerome KR, Greninger AL (2020) Pooling of SARS-CoV-2 samples to increase molecular testing throughput. J Clin Virol 131: 104570. doi: 10.1016/j.jcv.2020.104570.
- Valieris R, Drummond RD, Defelicibus A, Dias-Neto E, Rosales RA, Tojal da Silva I (2022) A mixture model for determining SARS-CoV-2 variant composition in pooled samples. Bioinformatics 38: 1809–1815. doi: 10.1093/bioinformatics/btac047.

Annex - Supplementary Items

Supprementary rable 1. The definitions of genotype groups at various levels of the original samples.
--

First-level classification	Second-level classification	Third-level classification	Genotype of original samples
Original	Original	В	В
8	8		- B 1 1 7
		D.1.1	D.1.1.407
			B.1.1.48/
		B.1.36	B.1.36
		Delta	B.1.617.2
			B.1.617.2.30
			B 1 617 2 36
			D.1.017.2.30
			B.1.61/.2.85
BA*	BA.1+BA.5	BA.1	BA.1
		BA.5.1	BA.5.1
		BA.5.1.3	BA.5.1.3
		BA 5 2 1*	BA 5 2 1
		D11.9.2.1	BA 5 2 1 7 14
		DA 527	DA.5.2.7
		BA.5.2./	BA.5.2.7
		BA.5.2.27	BA.5.2.27
		BA.5.2.48*	BA.5.2.48
			BA 5.2.48.1
			BA 5 2 48 2
			DA.5.2.40.2
			BA.5.2.48.5
		BA.5.2.49*	BA.5.2.49
			BA.5.2.49.2
	BA.2	BA.5.3.1*	BA.5.3.1.1.1
		BA 2 2*	BA 2 2 1
		BA 2 3*	BA 2 3 7
		DA.2.5	DA.2.3.7
		BA.2.10	BA.2.10
		BA.2.12*	BA.2.12.1.2
		BA.2.38	BA.2.38
		BA.2.75*	BA.2.75.1
			BA 2 75 5 1 2
		DA 276	DA 2 76
		DA.2.70	DA.2.70
		JN *	BA.2.80.1.1
			BA.2.86.1.1.1
			BA.2.86.1.1.1.1
XBB*	XBB*(excluding XBB.1.9*)	XBB.1	XBB.1
		XBB.1.5*	XBB.1.5
		1122110	VBB 154
			ADD.1.5.4 VDD 1.5.7
			ABB.1.3./
			XBB.1.5.15
			XBB.1.5.24.1
			XBB.1.5.59
		XBB.1.16*	XBB.1.16.1
			XBB 1 16 1 1
			VBB 1 16 2 1 1
			XDD.1.10.2.1.1
			ABB.1.10.5
			XBB.1.16.7
		XBB.1.17*	XBB.1.17.1.1
		XBB.1.18*	XBB.1.18.1.1.1
		XBB.1.19*	XBB 1.19 1.5 3.1
		VBB 1 /2*	VBB 1 42 1
		ADD.1.42* VDD 2.2*	ADD.1.42.1 VDD 2.2.2.1
		ABB.2.3*	ABB.2.3.2.1
	XBB.1.9*	XBB.1.9.1*	XBB.1.9.1.2
			XBB.1.9.1.5
			XBB.1.9.1.13
			XBB.1.9.1.15.2
			XBB 1 9 1 37
		VBB 1 0 2*	VBB 1 0 2 2
		ADD.1.).2	XDD.1.0.2.4
			ABB.1.9.2.4
			XBB.1.9.2.5.1.3.3
			XBB.1.9.2.5.1.1.3.3
		XBB.1.9.5*	XBB.1.9.5
Recombinants	Recombinants	XBF	XBF
		XBL 3	XBL 3
		VBC 1	XBC 162
		ADC.I	ABC.1.0.2
		ABU#	Omicron $(BA.2.76)$ + Omicron $(BA.5.2)$
		XBC#	Omicron (BA.2) + Delta (B.1.617.2*)
		XDD#	Omicron (EG.5.1.1) +Omicron (JN*)

*, including the lineage and its subtypes; #, simulated samples.

Supplementary Table 2. The original genotypes and the recovered genotypes of 70 simulated samples.

N 0.	Name			Original	l genotypes		Name						Recovered	genotypes							
1	M-1	B.1.1.7	BA.5.1	BA.2.10	XBB.1	JG.3	M-1	3490.46		0.747001806212		0 1021220040875									
		B.1.1.7	BA.5.1	BA.2.10	XBB.1	1.3.3		summarized	[('Omicron',	6736),	('Alpha',	294)]									
		\checkmark	BA.5.1.12	\checkmark		\checkmark		lineages	B.1.1.7	BA.2.10	BA.5	JG.3	BA.5.1. 12	XBB.1.5	XBB.1. 1	XU	XBB	EG.5	Q.7	EG.5.1. 8	BA.5.3
		1	BA.5.1.12	\checkmark	XBB.1.1	\checkmark		abundances	0.16897169	0.12384649	0.107868	0.10358644	0.09602	0.07438334	0.06180	0.05509775	0.05337	0.03120	0.02315	0.02271	0.01808
								resid	15.07037287		12		485		/15		512	199	13	81/	24
								coverage	99.84945301												
2	M-2	В	DY.3 BA.5.2.48.	BA.2.3.7	XBB.1.5	XBB.1.9.5	M-2	3693.13	F 440 1 1	0.717573625424		0.0769656771765									
		в	3	BA.2.3.7	XBB.1.5	ABB.1.9.5		summarized	[('Omicron',	9501),	(Other,	3452)]			VDD 1		D 1 1 52	VDD 1			
		B.50	\checkmark	1		\checkmark		lineages	BA.2.3.7	DY.3	8	XBB.1.9.5	B.50	XBB.1.9	5.49	B.1.1.161	9	44			
		B.50	\checkmark	\checkmark	XBB.1.5.49	\checkmark		abundances	0.25902808	0.17137134	0.098906	0.0802005	0.05224 083	0.04305058	0.03358 548	0.02472485	0.01784 808	0.01358 338			
								resid	12.11606923												
3	M-3	AV 30	BA 5 2 1	BA 2.76	HH 1	EG 2	M-3	2846.46	99.66210565												
5		B.1.617.2	BA 5 2 1	BA 2.76	XBB 2 3 2 1	XBB 1.9.2.2		summarized	[('Omicron'	0.757146079966	('Delta'	0.1458299330566	('Other'	0.025543412722							
		.30	BF=BA.5.	D.1.2.70	100.2.9.2.1	1			(Connector),	1878),	(Denu),	627),	(out),	42678)]					XBB.1.		XBB.2.
		N	2.1.X			V		lineages	EG.2	AY.30	BF.25	XM	BF.7	HH.1	BA.5	XBB.2.3.11	BA.5.2	B.1.1	5.28	FY.5	3.2
		\checkmark	BF7		\checkmark	\checkmark		abundances	0.28825317	0.14582993	13	0.07143909	34	0.05566293	629	0.04202304	595	341	22	661	829
								resid	17.49972036												
4	M-4	B.1.1.487	BA.5.2.27	JN.1	XBB.1.42.1	XBB.1.9.5	M-4	3293.72	99.05541407												
		B.1.1.487	BA.5.2.27	BA.2.86.1.1	XBB.1.42.1	XBB.1.9.5		summarized	[('Omicron',	0.816741328914	('Other',	0.0608784100741									
			1		2	1		lineager	VDD 1 42 1	1051), EG 2	DA 526	4000)] BA 5 2 27	XBB.1.	IN 10	VDD	VDV	DA 5	IN 1	VAU	XBB.1.	
								inicages	ADD:1.42.1	10.2	0.098328	BA.5.2.27	9.5 0.08456	514.10	0.06371	ABV	0.04144	0.03114	0.02108	9 0.01163	
			N	N	Ń	V		abundances	0.17739342	0.13326568	47	0.08899538	66	0.06516836	711	0.06087841	122	673	032	803	
								coverage	11.32067377 99.72901542												
5	M-5	B.1.1.487	BA.5.1.3	BA.2.2.1	GY.1.1	EG.4	M-5	3477.93													
		B.1.1.487	BA.5.1.3	BA.2.2.1	XBB.1.16.2.1. 1	XBB.1.9.2.4		summarized	[('Omicron',	0.927803864539 2129).	('Other',	0.0109728999878 63232)]									
			\checkmark	\checkmark		\checkmark		lineages	BA.2.73	BA.5.1.3	BA.2.2.1	EG.4	BA.2.10	GY.1	GY.1.1	B.1.1.487					
		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark		abundances	0.24956205	0.21641132	0.210573	0.14938617	0.05027 963	0.03904992	0.01254 177	0.0109729					
								resid	10.84962687												
								coverage	99.66210565	0 381433443933		0.1906032224041	COmicr	0.187709530190		0.139933479586					
6	C1-1	AY.85	B.1.36	AY.30	B.1.1.7	BE.1.1	C1-1	summarized	[('Delta',	112),	('Alpha',	9916),	on',	18025),	('Other',	7076)]					
		N	v+_27			1		lineages	A 1.85	BE.1.1	0.163974	B.1.36.27	0.11587	Q.7	0.01939	B.1.145					
		Ň	v+.27	Ň	N	Ň		abundances	0.24015889	0.18770955	82	0.12462686	868	0.0200284	587	0.01530062					
								coverage	14.91616776												
7	C1-2	B.1.1.487	B.1.36	B.1.36	В	BA.5.2.7	C1-2	summarized	[('Other',	0.459861347102 91543),	('Omicro n',	0.1738207872757 6097)]									
		\checkmark	√+.27	√+.27	\checkmark	\checkmark		lineages	B.1.36.27	BA.5.2.7	в	B.1.1.487	B.1.1.18	B.1.1.161	BA.5.2.						
		1	√+.27	√+.27	1	1		abundances	0.34494781	0.16114223	0.058810	0.023105	0.01798	0.01501758	0.01267						
								resid	11.86773911		61		034		856						
								coverage	100												
			_	_						0 385825975735	COmicro	0.3471621720112		0.138300722787							
8	C1-3	B.1.1.487	в	В	B.1.617.2	BA.2.2.1	C1-3	summarized	[('Other',	5056),	n',	029),	('Delta',	54357)]							
		√487	N	N	v+.29	N .1		lineages	B.1.1	BA.2.2.1	B 0.139779	AY.9	XAP 0.09312	B.1.1.529							
		148/	~	Ň	1+.29	Ň		abundances	0.24004004	0.207222	34	0.13830072	467	0.04681551							
								coverage	99.81265264												
9	C1-4	AY.85	B.1.36	AY.85	B.1.1.7	JN.1	C1-4	summarized	[('Delta',	0.467501000000 17036),	('Other',	0.1799593483993 398),	('Alpha',	0.179954634489 7931),	('Omicr on',	0.092083997057 47791)]					
		~	√+.27	\checkmark	\checkmark	\checkmark		lineages	AY.85	B.1.1.7	B.1.36.2	JN.1	JN.10	B.1.143	Q.7	BA.2					
		1	√+.27	1	1	1		abundances	0.467501	0.16135263	0.145995	0.04226986	0.03845	0.03396344	0.01860	0.01136083					
								resid	19.21065208		9		331		2						
								coverage	100												
										0 256927115569	COmiaro	0 2794210770292		0 105110422023							
10	C1-5	в	в	AY.36	B.1.36	BA.2.75.1	C1-5	summarized	[('Other',	71616),	n',	0765),	('Delta',	69396)]							
		1	\checkmark	\checkmark	√+.27	\checkmark		lineages	BA.2.75.1	в	B.1.30.2 7	AY.36	AY.1	B.1.1.529							
		\checkmark	\checkmark	\checkmark	√+.27	\checkmark		abundances	0.23516187	0.21393912	0.142888	0.141651	0.05345 942	0.04326921							
								resid	13.30071832												
								coverage	100												
11	C2-1	R	B136	B117	BA 5 2 1	BA 513	C2-1	summarized	[('Omicron'	0.378108585228	('Other'	0.2880143130983	('Alnho'	0.177734761996							
	02.	1	√+ 27	1	1			lineages	BA 5.2.1	21666), B 1 36 27	BA 5.3	9853), B 1 1 7	B	55625)] BA 5 1 3	0.7						
		1	~	1	1	1		abundances	0.17699206	0.161333	0.132709	0.13127296	0.12668	0.06840745	0.04646						
								resid	13.41153674		07		131		18						
								coverage	100												
										0 312509805547		0 2781763953398		0 168532999994							
12	C2-2	в	AY.36	B.1.36	BA.1	BE.1.1	C2-2	summarized	[('Omicron',	9885),	('Other',	677),	('Delta',	40222)]							
		V	N.	√+.27	V	1		lineages	BE.1.1	AY.36	B 0.140817	B.1.36.27	BA.1 0.10987								
		V	V	√+.27	V	V		abundances	0.20263179	0.168533	4	0.137359	801								
								resid	10.50144275												
								ge	100												
13	C2-3	AY.85	в	B.1.36	BA.1	BA.5.1	C2-3	summarized	[('Other',	0.351994403523	('Delta',	0.3087980000074	('Omicr	0.170101131568							
		\checkmark	\checkmark	√+.27	\checkmark			lineages	AY.85	В	B.1.36.2	BA.1	B.1.143	BA.5.1.6	BA.5.3						
		J	1	√+ 27	1	√+ 6		ahundances	0.308798	0 14344643	/ 0.139746	0.11476482	0.06880	0.02939109	0.02594						
		,		e :	×	11.0		resid	12.2060864	0.17077040	91	0.117/0403	106	0.02939109	52						
								coverage	100												
										0.26720-6777	aco . :	0.0100400000000000000000000000000000000		0.010000000							
14	C2-4	B.1.1.7	в	B.1.36	BA.5.1.3	BG.2	C2-4	summarized	[('Other',	0.357296757721 5377),	('Omicro n',	0.31/2479766684 1953),	('Alpha',	0.210252005021 54973)]							
		\checkmark	\checkmark	√+.27		\checkmark		lineages	B.1.36.27	B.1.1.7	BA.5.3	в	BG.2	BA.5.1.3	B.1.1.16 1	Q.7	BA.3				
		\checkmark	\checkmark	√+.27	\checkmark	\checkmark		abundances	0.17716	0.16871851	0.149502	0.12947869	0.07860	0.06789862	0.05065	0.0415335	0.02124				
								resid	12.96847009		40		012		6U/		0//				
								coverage	100												
	(****	D + + +~~	D 1 37	A 37 4 -	D+ 645	DF 11			100 1	0.410865226894	004 -	0.2058792701726	05.1.1	0.183322999877							
15	C2-5	в.1.1.487	в.1.36	AY.36	вА.5.2.7	BE.1.1	C2-5	summarized	[(Umicron',	85083),	('Other',	0454),	('Delta',	24723)]							
			√+.27	1	V	1		lineages	BE.1.1	B.1.36.27	AY.36	BA.5.2.7	8	B.1.533							

Chen et al. - Evaluation of pooled sequencing of SARS-CoV-2

			√+.27	1	1	1		abundances	0.21538579	0.189087	0.183323	0.17683529	0.01864	0.01679227						
								resid	11.87066011				415							
								coverage	100											
16	C3-1	B.1.1.487	BA.2.2.1	BA.2.10	BA.5.2.27	BA.2.75.1	C3-1	summarized	[('Omicron',	0.923144320247 8207)]										
			~	1	1	√1		lineages	BA.5.2.27	BA.2.2.1	BA.2.75	BA.2.10	BA.2.2	BA.2.75.1	XAH 0.05846	XBD	BA.5			
			Ń	V	V	~		abundances	0.18585591	0.182348	99	0.10654654	599	0.06528333	714	0.05090689	553			
								coverage	99.84276204											
17	C2 2	D 1 26	DA 227	DA 527	DI 1.2	DA 2751	C2 2		[((Omission))	0.720146623342	(Others)	0.1678333923339								
17	C3-2	B.1.30	BA.2.3.7	BA.5.2.7	JN.1.3	BA.2.75.1	C3-2	summarized	[(Omicron',	2218),	(Other, B.1.36.2	0127)]	D. I	D1.2/2	BA.5.2.	D.1.2				
		v+.27			s	N		incages	BA.2.3.7	BA.2.75.1	7 0.167833	BA.5.2.7	JN.1 0.07704	BA.2.05	8 0.03333	BA.3				
		v+.27	Ň	v	۷5	Ň		resid	12.62601975	0.196/888	39	0.12131143	404	0.05/350/6	964	0.01800087				
								coverage	100											
18	C3-3	AY 36	BA 5.1	BA 2 3 7	BG 2	BA 2.10	C3-3	summarized	[('Omicron'	0.782625736552	('Delta'	0.1883780000061								
		1	1	1	~	1		lineages	BA.2.3.7	486), AY.36	BA.5.1	6334)] BA.2.10	BG.2	XJ	XAH	XE	BA.2.12	BA.5	BA.5.3	
		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark		abundances	0.266403	0.188378	0.127502 9	0.11268825	0.08913 02	0.07867812	0.02958 619	0.02914365	0.01836 622	0.01613 895	0.01498 825	
								resid coverage	12.1198468 99.90967181											
19	C3-4	B.1.36	BA.2.38	BA.5.2.1	BA.5.2.27	BN.1.2	C3-4	summarized	[('Omicron',	0.702426908298 9902),	('Other',	0.1918451406459 4316)]								
		√+.27	~	√+.28	\checkmark	\checkmark		lineages	BN.1.2	B.1.36.27	BA.5.2.2 7	BF.28	BA.2.38	XBD	BA.3					
		√+.27	\checkmark	√+.28	\checkmark	\checkmark		abundances	0.19555445	0.19184514	0.184603 78	0.13599178	0.12589	0.03502579	0.02535 961					
								resid coverage	11.37562092 100											
										0 794890555268		0 1382305776120								
20	C3-5	в	BA.5.2.49	BA.2.2.1	BA.1	BA.2.76	C3-5	summarized	[('Omicron',	7626),	('Other', BA 5.2.4	0525)]	B 1 1 52		BA 5.2					
		N	N	V				lineages	BA.2.2.1	XM	9	В	9	DZ.1	6	B.1.1.161	BA.1	BA.1.6		
		~	\checkmark	\checkmark	V			abundances	0.2196609	0.2173996	66	0.10349989	543	0.06986034	753	0.03473069	343	467		
								coverage	99.71563347											
21	C (1)	D. 607	D 4 2 20	D1 (12	DV 3	VDD 1.5.4	611		100 1	0.966186841639										
21	C4-1	BA.5.2.7	BA.2.58	BA.5.1.5	DY.3	ABB.1.5.4	C4-1	summarized	[(Umicron',	8551)]	D	XDD 1.6.4	BA.5.1.	VDD 1.4	N A TI	D. C	D. 62	BA.5.2.		
				N ./		N		incages	0224255445	BA.5.2.7	BA.2.38	ABB.1.5.4	3 0.14892	ABB.1.4	0.01971	BA.5	0.01333	8 0.01275		
		N	N	v	N	N		abundances	0.22425645	0.18//55	0.162162	0.16156/4/	508	0.02016377	354	0.01554885	695	773		
								coverage	99.24057409											
22	C4-2	BA.5.2.2	DZ 2	BG 2	BE 1.1	HH 1	C4-2	summarized	[('Omicron'	0.962736475288										
	012	7	1	1	1		012	lineages	DZ 2	2939)] BE 1.1	BA.5.2.2	BG 2	BA 2.65	HH 1	BA 5					
		√	1	1	, √	1		abundances	0.25492772	0.24961696	7 0.227053	0.08692386	0.06905	0.0455975	0.02956					
								resid	6.269630773	0.21/010/0	0.2270000	0.00072500	53	0.04009710	214					
								coverage	99.24057409											
23	C4-3	BA.5.1	BE.1.1	BA.5.1.3	BA.1	FL.2	C4-3	summarized	[('Omicron',	0.959110119922										
		√+.3	1	1	~	\checkmark		lineages	FL.2	4349)J BE.1.1	BA.5.1.3	XM	BA.1	BA.5.3	BA.5.3.	BA.1.6				
		√+.3	\checkmark	\checkmark	\checkmark	\checkmark		abundances	0.23268755	0.23205519	0.201976	0.14863133	0.07235	0.02762413	0.02595	0.01782949				
								resid	8.258771416		80		232		022					
								coverage	99.71563347											
24	C4-4	BA.5.1	BA.5.2.49	BA.2.75.1	BA.5.1.3	GY.1.1	C4-4	summarized	[('Omicron',	0.944603273560										
			\checkmark	\checkmark	\checkmark			lineages	BA.2.75.1	BA.5.1.3	DZ.1	BA.2.10	XAS	BA.5.2.8	BA.5.2. 49	GY.1	BA.2.64	BA.2.75	BA.2.12	GY.2
		\checkmark	\checkmark	\checkmark	\checkmark	√1		abundances	0.25421276	0.23498074	0.103739	0.0846719	0.06039 242	0.05048337	0.03608	0.03105092	0.02851 116	0.02590 645	0.01798 0	.01657 892
								resid	9.938431285											
								coverage	99.24057409											
25	C4-5	BA.5.1.3	BA.2.10	BG.2	BE.1.1	GW.5.3.1	C4-5	summarized	[('Omicron',	0.979435972944 1638)]										
		\checkmark	\checkmark		\checkmark	\checkmark		lineages	BE.1.1	BA.5.1.3	BA.2.10	GW.5.3.1	BA.2.65	GW.5	BG.2	BA.2.12	BA.5.1. 12	XAS	XBB.1. B 19.1	A.2.12
		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark		abundances	0.21707397	0.15457818	0.119997 8	0.115117	0.08631 458	0.07521658	0.07184 944	0.04969711	0.03385 127	0.02794 94	0.01550 0 26	0.01228 804
								resid coverage	8.700227434 99.83941655											
										0.042050970424										
26	C5-1	BA.5.2.1	BA.5.1.3	BA.5.2.27	XBB.1.16.1	XBB.1.9.5	C5-1	summarized	[('Omicron',	2044)]	VDD 1 1		VDD 1		VDD 1		VDD 1			
		√+.3	1	1		\checkmark		lineages	BA.5.1.3	BA.5.2.27	6.11 0.1502(1	BF.3	9.5 9.5	BA.5.2.4	ABB.1. 9	BF.28	16.1	FY.5		
		√+.3	1	1	~	\checkmark		abundances	0.1785886	0.1640464	72	0.08580602	01	0.07586072	53	0.05811424	7	0.04324		
								coverage	6.104626099 99.24057409											
										0.962636760987										
27	C5-2	BA.2.3.7	BA.2.10	JN.1	XBB.1.16.1	EG.2	C5-2	summarized	[('Omicron',	2303)]					VDD 1					
		~	1		1	1		lineages	BA.2.3.7	XBB.1.16.1	EG.2 0.172447	BA.2.10	BA.2.1 0.10057	JN.1	9.2					
		N	Ń	V	V	~		abundances	0.242808	0.17938343	88	0.15609039	69	0.08667896	12					
								coverage	99.89628985											
20	C5.2	BA.5.2.2	PC 2	DA 5 3 40	VDD 1 5 16	VDD 1 42 7	(15.)	cummerice d	[//Om:!	0.915426147489	(Other	0.0361315521839								
28	C3-3	7	ыц.2 Л	DA.3.2.49	лов.1.5.15	лов.1.42.1	CS-3	liner	VDD 1 42 1	491),	(Other',	41644)]	PC 2	D7 1	YDV	DAE	XBB.1.	VPD	BA.5.2.	
		×	N J	v al	v=.2	* 1		abund	0.22220222	0.22052465	0.181911	0.08605290	0.07484	0.06500490	0.03613	0.02209492	5.15 0.01815	0.01236	6 0.01099	
		v	v	v	v+.2	v		resid	6.664668931	0.22052465	22	0.08005289	343	0.00209688	155	0.02308482	525	55	917	
								coverage	99.24057409											
29	C5-4	BG 2	BA.2.2.1	BA.2.10	FE 1.1	XBB 1 9 5	C5-4	summarized	[('Omicron'	0.957296771148										
		1	1	√	1			lineages	BA.2.2.1	0168)] FE.1.1	BA.2.10	FL.2.4	BG.2	BA.2.65	XBB.1.	BA.2.2	XBB.1.			
		~	1	1	1	~		abundances	0.211712	0.16979661	0.127303	0.09958206	0.07952	0.07809989	0.06598	0.063838	9.5 0.06145			
								resid	7.569574172		48		91		522		04			
								coverage	99.83941655											
30	C5-5	BA.2.38	BA.2.3.7	BE.1.1	FL.13	GW.5.3.1	C5-5	summarized	[('Omicron',	0.916602324320	('Other',	0.0547419127590								
		~	1	1	√+.1			lineages	BE.1.1	BA.2.3.7	FL.13.1	BA.2.38	BA.2.10	GW.5.3.1	XDE	BA.2.1	FL.13	FL.25	BA.5.3.	

Chen et al. – Evaluation of pooled sequencing of SARS-CoV-2

		V	1	V	√+.1	4		abundances resid coverage	0.18470767 8.285413483 99.24057409	0.17993168	0.13152	0.12300457	0.11430 02	0.07708367	0.05474 191	0.04724363	0.02503 157	0.02010 626	0.01367 307		
31	C6-1	BA.5.2.7	GA.1	GW.5.3.1	FL.2	XBB.1.42.1	C6-1	summarized	[('Omicron',	0.912403273540 6497),	('Other',	0.0484339660031 9554)]	GW 5.3		VDD 1		VDD 1	VDD 1	DA 5 2		
		V	1	1	1	~		lineages	FL.2	XBB.1.42.1	GA.1	BA.5.2.7	1	XDE	19	BA.5.2.6	17.1	19.1	23 0.01603		
		V	V	V	~	1		abundances	0.19936228	0.1899798	0.161707	0.13118977	54	0.04843397	153	0.0343417	648	949	982		
								coverage	99.24057409												
32	C6-2	DZ.2	XBB.1.9.5	XBB.1	GW.5.3.1	XBB.1.42.1	C6-2	summarized	[('Omicron',	0.902808563554	('Other',	0.0463841479829									
		\checkmark	~	√+.5.28	~	~		lineages	DZ.2	8736), XBB.1.42.1	XBB.1.5.	GW.5.3.1	XBB.1.	XBB.1.5.40	XBB.1.	XBB.1.9.5	BA.5.2	XDE	XBB.1.	XBB.1.	EG.2
		\checkmark	\checkmark	~	\checkmark	~		abundances	0.18897432	0.17542771	0.101982	0.0701092	0.06336	0.05670855	0.05182	0.0507937	0.04955	0.04638	0.04075	0.02616	0.01510
								resid	9.473359853		2		807		001		038	415	924	111	392
								coverage	99.66210565												
33	C6-3	BA.2.76	GA.1	XBB.1.9.5	XBB.1.42.1	XBB.1.5	C6-3	summarized	[('Omicron',	0.942316185469 6444)]											
		\checkmark	\checkmark	1	\checkmark	√+.28		lineages	XBB.1.42.1	GA.1	XBB.1.5. 28	XBB.1.9.5	BA.2.76	XBB.1.5.77	XBB.1. 17	XBB.1.9	XBB.1. 17.1	XBB.1. 22			
		\checkmark	\checkmark	\checkmark	\checkmark	√+.28		abundances	0.21228635	0.148991	0.085726 6	0.0845666	0.08303 346	0.07936591	0.07840 98	0.07645132	0.06609 282	0.02739 232			
								resid coverage	5.224898071 99.24057409												
24	<i>C(1</i>	D. 61	VDD 1	FF 1 1	64.1	FT 12	<i>c(1</i>		[//O]	0.967381902714											
54	C0-4	ВА.5.1 √	×H.5	FE.1.1 √	GA.I √	√+.1	C6-4	lineages	XBB.1.5	2181)] GA.1	FE.1.1	BA.5.1	FL.13.1	FL.2.4	BA.5	XBB.1.39	XBB				
		\checkmark	√+.5	\checkmark	\checkmark	√+.1		abundances	0.23349935	0.16269731	0.139669 63	0.10578073	0.10104 7	0.0768053	0.05353 26	0.04885701	0.04549 298				
								resid	6.802805585 99.66210565												
			VDD 1.42							0.062025211444											
35	C6-5	BG.2	1	HK.3.3	XBB.1	FL.2	C6-5	summarized	[('Omicron',	6671)]	XBB 1.4										
		N	N.	N.	√+.5.28	N.		lineages	HK.3.3	FL.2	2.1 0.192560	XBB.1.5.28	BG.2 0.07323	XBB.1.39	XBB.1 0.06180	HK.3					
		V	N	N	N	N		abundances	0.212742	0.19975814 0.436486620696	73	0.12826264 0.2890008239099	582	0.06399994	641	0.03066963					
50	1-0-1	В	B.1.1.487 B.1.1.487	AY.30 B.1.617.2.30	B.1.617.2 B.1.617.2	B.1.36 B.1.36	1-0-1	lineages	[('Other', B.1.36.27	8294), AY.30	('Delta', AY.24	724)] B	B.1.1	B.1.551	B.1						
		\checkmark	B.1+B.1.5 51	\checkmark	√+.24	√+.27		abundances	0.15151737	0.14952757	0.139473 26	0.08448467	0.08008 201	0.06213698	0.05826 559						
		\checkmark	B.1+B.1.5 51	\checkmark	√+.24	√+.27		resid	8.876707977												
								coverage	100												
37	T-O-2	AY.85	AY.36	в	B.1.617.2	B.1.1.7	T-O-2	summarized	[('Delta',	0.670016704098 4318).	('Alpha',	0.1735574070020 4708).	('Other',	0.101021154304 85181)]							
		B.1.617.2 .85	B.1.617.2. 36	в	B.1.617.2	B.1.1.7		lineages	AY.85	B.1.1.7	B.1.617. 2	AY.36	в	AY.9	Q.7	AY.106					
		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark		abundances	0.29673	0.14200401	0.139957 61	0.13856292	0.10102 115	0.07866277	0.03155 34	0.01610339					
		\checkmark	1	~	~	~		resid coverage	10.63130576 99.90298083												
										0.436174277526		0 3578289703622									
38	T-O-3	B.1.617.2 B.1.617.2	в	AY.36 B 1 617 2 36	AY.30 B 1.617.2.30	B.1.36 B.1.36	T-O-3	summarized lineages	[('Delta', B	9694), AY 30	('Other', AY 36	396)] B 1 36 27	AV.9	B1							
		√+.9	1	1	√	√+.27		abundances	0.18455915	0.17613983	0.172596	0.155794	0.08743	0.01747582							
		√+.9	\checkmark	\checkmark	\checkmark	√+.27		resid	9.606708161				011								
								coverage	100	0 201460262620		0 2000/05011001		0.226506502008							
39	T-O-4	B.1.1.487	B.1.1.7	B.1.617.2	B.1.36	AY.30	T-O-4	summarized	[('Other',	8053),	('Delta',	0.2900685811981 087),	('Alpha',	5385)]							
		B.1.1.487 B.1+B.1	B.1.1.7	B.1.617.2	B.1.36	B.1.617.2.30		lineages	B.1.1.7	AY.30	7	AY.9	B.1.551 0.08268	B.1	Q.7 0.06316						
		551 B.1+B.1.	N.	√+.9	v+.27	N		abundances	0.1733384	0.15800221	14	0.13206637	694	0.06612618	81						
		551	v	17.9	17.27	×.		coverage	10.99183487												
40	TOF	D 1 617.2	D117	D 1 1 497	AX 20	AV 26	TOF		[//D_lt_l	0.701115697815	(Alabel	0.2180950978371	(0)h	0.033681799983							
40	1-0-5	B.1.617.2	B.1.1.7	B.1.1.487	B 1 617 2 30	B 1 617 2 36	1-0-5	lineages	AV 36	0622), AV 30	B117	2383), B 1 617 2	av 9	64558)]	B.1.1.48						
		J	1	x	J	J		abundances	0.247664	0 18991547	0.163701	0.14812005	0.11541	0.0543933	7 0.03368						
		1	1	1	1	1		resid	8.264774461		8		617		18						
								coverage	99.85614399												
41	T-BA-1	BA.5.2.4 8	JN.1	BA.5.2.1	BA.2.10	JN.1.1	T-BA-1	summarized	[('Omicron',	0.894472650974 5479)]											
		BA.5.2.4 8	BA.2.86.1. 1	BA.5.2.1	BA.2.10	BA.2.86.1.1. 1		lineages	BA.2.10	BF.25	BA.5.2.4 8	JN.1.1	BA.2.1	BA.2.56	BA.2.16	JN.3	JN.1	CT.1	BA.5.2. 9	JN.8	BA.5.2. 8
		V	√1	√+.25	1	1		abundances	0.1373305	0.12714003	0.106908 52	0.10521356	0.07799 6	0.05937536	0.05654 601	0.04756187	0.04617 08	0.03799 002	0.03170 054	0.03066 53	0.02987 413
		V	V	√+.25	~	V		resid coverage	14.16768055 99.89628985												
42	T DA 2	DC 2	DV 2	IN 1.1	DA 5 2 27	IN 1.2	T DA 2		[//Ominum!	0.978743550180											
42	1-DA-2	BG.2 BA.2.12.	BA.5.2.48.	DA 2 86 1 1 1	BA.5.2.27	BA.2.86.1.1.	1-BA-2	lineages	DV 3	9867)] XAS	IN 1.1	DA 5 2 27	PG 2	IN 2	DA 265	IN 10	BA.2.86				
		1.2	3	J	J	3 IN 1-1		abundances	0 25444789	0 18961847	0.172813	0.16552575	0.09381	0.05058857	0.02546	0.014729	.1 0.01173				
		Ń	1	v.	v.	JN.1.1		resid	14.18306557	0.13901047	96	0.10552575	627	0.05058857	783	0.014729	582				
								coverage	99.72566993												
43	T-BA-3	BA.5.1.3	BG.2	BE.1.1	DY.1	DZ.2	T-BA-3	summarized	[('Omicron',	0.976200127096 6906)]											
		BA.5.1.3	BA.2.12.1. 2	BA.5.3.1.1.1	BA.5.2.48.1	BA.5.2.49.2		lineages	DZ.2	BE.1.1	DY.1	BA.5.1.3	BG.2	BA.5.2	XAS	BA.2.65	BA.5.3	BA.5	BA.2.12	BA.5.2. 59	
		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark		abundances	0.22466177	0.19784601	0.189772 95	0.12130919	0.06937 039	0.05857305	0.04088 57	0.01778967	0.01663 876	0.01654 271	0.01196 494	0.01084 501	÷
		V	1	\checkmark	~	\checkmark		resid coverage	5.223142034 99.24057409												
									500 L .	0.929454649359											
44	1-BA-4	DY.3 BA.5.2.4	JN.1 BA.2.86.1.	BA.5.2.1	BF.7.14	BA.2.3.7	1-BA-4	summarized	[('Umicron',	7126)]	DADD	DE 7 14 4	IN 1	DE 7 14	DE 20	DA 21	BA.2.86				
		8.3 √	1	BF 7 14 6	JA.J.2.1.7.14 √+ 6	J		ahundances	0.248793	0.236102	0.135531	0.1195046	0.07349	0.04528763	0.03328	0.0250589	.1 0.01240				
		1	, J	BF.7.14.6+BF	√+ K	, 1		resid	11.01379641	0.200102	86	0.1199040	447	0.04020700	135	0.0200009	084				
				.7.14				coverage	99.72901542												
45	T-RA 5	BF 1 1	BA 2 2 1	JN 1.2	RG 2	BN 1.2	T. D.A. F	summarized	[('Omicron'	0.965865111071											
45	. 54-5	BA.5.3.1.	BA.2.2.1	BA.2.86 1 1 3	BA.2.12.1.2	BA.2.75.5.1.	1-04-3	lineages	BN.1.2	3212)] BA.2.2.1	BE.1.1	BA.2.65	JN 1	BG.2	JN.3						
		1.1 √	1	JN.1		2 √		abundances	0.24984843	0.226729	0.216875	0.09981632	0.08018	0.07455413	0.01785						

		Å	V	JN.1	1	1			resid coverage	9.115234643 99.70225151								
											0.001044799972							
46	T-XBB-1	GA.1 XBB.1.1	FL.15.2 XBB 1 9 1	FU.1	GF.1	EG.4		T-XBB-1	summarized	[('Omicron',	7193)]			XBB 1				
		7.1.1	15.2	XBB.1.16.1.1	XBB.1.5.24.1	XBB.1.9.2.4			lineages	FL.15.2	FU.1	GF.1	GA.1	22 0.10654	EG.4	EG.4.5 0.04044		
		N J	1	1	N N	~			abundances	0.207345	0.186711	0.17371	0.171276	398	0.10591516	364		
		,	v	,	•	× ×			coverage	99.66210565								
47	T-XBB-2	XBB.1.5.	EG.2	XBB.1.42.1	XBB.1.16.7	XBB.1.5.7		T-XBB-2	summarized	[('Omicron'.	0.956078092835	('Other'.	0.0286782967121					
		15 XBB.1.5.	XBB.1.9.2.	XBB.1.42.1	XBB.1.16.7	XBB.1.5.7			lineages	EG.2	6013), XBB.1.16.7	XBB.1.4	09985)] FD.2	XBB.1.	XBB.1.5.28	XBB.1.	XDB	FL.26
		15	2	1	1	1			abundances	0.1892664	0.187998	0.187418	0.13909135	5.7 0.10460	0.07861877	0.04313	0.0286783	0.02594
		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark			resid	5.390827566		23		048		545		943
									coverage	99.24057409								
48	T-XBB-3	XBB.1.5. 7	XBB.1.9.5	HK.3.3	XBB.1.16.3	XBB.1.16.7		T-XBB-3	summarized	[('Omicron',	0.972344472647 3409)]							
		XBB.1.5. 7	XBB.1.9.5	XBB.1.9.2.5.1 .1.3.3	XBB.1.16.3	XBB.1.16.7			lineages	HK.3.3	XBB.1.5.7	XBB.1.1 6.7	XBB.1.16.11	XBB.1. 9.5	XBB.1.16.3	XBB.1. 9	XBB.1.38	
		\checkmark	\checkmark	\checkmark		\checkmark			abundances	0.22395934	0.20642279	0.184438 73	0.09168624	0.08933 56	0.0740173	0.07026 219	0.03222227	
		\checkmark	V	\checkmark	1	\checkmark			resid coverage	5.378501768 99.24057409								
											0 773760353973		0 2062711609927					
49	T-XBB-4	FL.2 XBB 1.9	EG.4 XBB 1 9 2	XBB.1.5.15	XBB.1.16.7	GY.1.1 XBB 1 16 2		T-XBB-4	summarized	[('Omicron',	3726),	('Other',	7526)]					
		1.2	4	XBB.1.5.15	XBB.1.16.7	1.1			lineages	FL.2	XDB	EG.4 0.179270	XBB.1.16.7	FD.2 0.10826	XBB.1.5.15	GY.1 0.02771	GY.1.1	
		N N	N N	1	N V	~			abundances	0.21595558 5.725339508	0.2062/116	4	0.159914	674	0.07093653	765	0.01169945	
									coverage	99.66210565								
50	T-XBB-5	XBB.1.1	XBB.1.5.1	FU.1	HH.1	GF.1		T-XBB-5	summarized	[('Omicron'.	0.972090924856							
		0.7 XBB.1.1	XBB.1.5.1	XBB.1.16.1.1	XBB.2.3.2.1	XBB.1.5.24.			lineages	FU.1	XBB.1.16.7	GF.1	FD.2	XBB.1.	XBB.1.38	HH.1	XBB.2.3.11	XBB.1.
		0.7	·	~		1			abundances	0.22659924	0.2030749	0.180876	0.15541526	0.08307	0.03618252	0.03295	0.0299574	0.02394
		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark			resid	5.907637161				923		095		941
51	S-Delta	B.1.617.2	AY.30	AY.36	AY.85			S-Delta	coverage	99.24057409								
		B.1.617.2	B.1.617.2. 30	B.1.617.2.36	B.1.617.2.85				summarized	[('Delta',	0.960891295556 471)]							
		√+.9	\checkmark	\checkmark	\checkmark				lineages	AY.85	AY.36	AY.30	AY.9	B.1.617. 2	AY.106			
		\checkmark	\checkmark	\checkmark	\checkmark				abundances	0.350789	0.20138653	0.179245 21	0.12958701	0.05912 3	0.04076055			
									resid	8.96947828 99.85614399								
52	S-XBB.1.5	XBB.1.5	XBB.1.5.4	XBB.1.5.7	XBB.1.5.15	GF.1 XBI	B.1.5.59	S-XBB.1.5	corciage	<i>)).000140))</i>	0.000530531053							
		XBB.1.5	XBB.1.5.4	XBB.1.5.7	XBB.1.5.15	1	5.59		summarized	[('Omicron',	3057)]			VDD 1		VDD 1		
		√+.52		~	√+.2	\checkmark	\checkmark		lineages	XBB.1.5.52	XBB.1.5.7	GF.1	FD.2	5.59	XBB.1.5.4	5.57	XBB.1.5.15	
		√+.52	V	~	√+.2	\checkmark	~		abundances	0.251357	0.23939399	0.136602	0.12675504	023	0.07490757	814	0.01786456	
									coverage	99.24057409								
53	S- XBB.1.9.1	FL.2	FL.5	FL.13	FL.15.2	FL.37		S- XBB.1.9.1										
		XBB.1.9. 1.2	XBB.1.9.1. 5	XBB.1.9.1.13	XBB.1.9.1.15. 2	XBB.1.9.1.3 7			summarized	[('Omicron',	0.996336463645 9155)]							
		1	1	√+.1 √+ 1	1	1			lineages	FL.2	FL.15.2	FL.13.1	FL.5	FL.37 0.03746				
		,	v	v	,	× ·			resid	4.374682919	0.232951	0.1021/1	0.11004192	77				
	5							S-	coverage	99.24057409								
54	XBB.1.9.2	EG.2 XBB 1.9	EG.4 XBB 1 9 2	JG.3 XBB 1 9 2 5 1	HK.3.3 XBB 1 9 2 5 1			XBB.1.9.2			0.992517303629							
		2.2	4	.3.3	.1.3.3				summarized	[('Omicron',	3141)]				20.1	XBB.1.		
		N	v+.5	N	N				lineages	HK.3.3	EG.4.5	EG.2 0.164331	JG.3	HK.3 0.05749	EG.4	9.2 0.03767	EG.5.1.3	
		v	v+.5	Ň	Ň				resid	3.730787777	0.23217819	76	0.14210117	172	0.04036108	566	0.01159971	
		XBB 1.1							coverage	99.66210565								
55	S-XBB.1.16	6.1 XBB 1.1	FU.1 XBB 1 16	GY.1.1 XBB 1 16 2 1	XBB.1.16.3	XBB.1.16.7		S-XBB.1.16			0 980473217935							
		6.1	1.1	1	XBB.1.16.3	XBB.1.16.7			summarized	[('Omicron',	9572)]	XBB.1.1		XBB.1.				
		N	Ň	v1.1	N	N			lineages	XBB.1.16.1	FU.I	6.7	XBB.1.16.3	16.2 0.05494	XBB.1.16.8	GY.1 0.02375		
		N	N	V1	N	N			abundances resid	0.34338105 4.183898482	0.23132692	0.180227	0.0997926	137	0.047046	828		
51	C IN	DV 1	IN 1-1	IN 1.2				C INI	coverage	99.24057409								
20	S-JN	JN.1 BA.2.86.	JN.1.1 BA.2.86.1.	JN.1.3 BA.2.86.1.1.3				S-JIN	summarized	[('Omicron'.	0.992877849555							
		1.1	1.1						lineages	JN.1	3126)] JN.1.1							
		V	V						abundances resid	0.66123224 6.662507217	0.33164561							
							BA 5.2		coverage	99.85614399								
57	S-BA.5.2	BA.5.2.1	BF.7.14 BA 5 2 1 7	BA.5.2.7	BA.5.2.27	BA.5.2.48	49 BA 5 2	S-BA.5.2			0.945181968653							
		BA.5.2.1	.14	BA.5.2.7	BA.5.2.27	BA.5.2.48	49		summarized	[('Omicron',	4857)]			BF 7 14				
		√+.28	√+.6	1	V	√+.3	√+.1		lineages	BA.5.2.27	BF.28	BA.5.2.7	DY.3	.6	DZ.1	BF.7.14 0.08527		
		√+.28	√+.6	1	V	√+.3	√+.1		abundances	0.21092499	0.16725912	0.154764	0.12968135	124	0.0927509	037		
	c							c	coverage	99.66210565								
58	BA.5.2.48+ 49	BA.5.2.4 8	DY.1	DY.2	DY.3	BA.5.2.49	DZ.2	BA.5.2.48+										
	.,	BA.5.2.4 8	BA.5.2.48.	BA.5.2.48.2	BA.5.2.48.3	BA.5.2.49	BA.5.2. 49.2	.,	summarized	[('Omicron',	0.971859458890 4457)1							
		√+?	V	√	1	√+.1	V		lineages	DY.2	DY.3	DZ.2	DY.1	DZ.1 0.07821	BA.5.2.44			
		√+?	V	~	V	√+.1	~		abundances	0.278361	0.254268	0.175951	0.15907224	1	0.02599622			
									coverage	99.66210565								
59	2023-19- CX251	XBF						2023-19- CX251	summarized	[('Omicron', 0.993831671981452								
		1							lineages	2)J XBF								
		V							abundances resid	0.99383167 8.997579584								
									coverage	99.23388311								
60	2023-19- CX611	XBL.3						2023-19- CX611	summarized	[('Other',	0.998728367967							
	1	1							lineages	XBL.3	XBL 0.10072701							

				re cov	esid erage	4.64860405 99.39112107				
61	2023-19-	XBC.1.6.		2023-19-	marizad	[('Other'	0.999103040998			
01	CX2945	2		CX2945	angac	VPC 1.6.1	8897)]			
		1		abun	idances	0.99910304				
				re	esid	4.847309135				
				cov	erage	96.07239637				
62	XBG-1	BA 2.76	BA 5 2 7	XBG-1						
02	And I	1	1		marizad	[(Omigran)	0.982806469533			
		1	1	line	angac	PA 527	7266)] PA 2 76	DA 526	DE 7	
		,	•	abum	.ages vdancar	0.67152261	0.22261212	0.053099	0.03456206	
					uances	5 261721941	0.22501212	68	0.05450200	
				10 COV	erage	99.24057409				
63	XBG-2	BA.2.76	DY.3	XBG-2	0					
		\checkmark	\checkmark	sumn	narized	[('Omicron',	0.981610414677			
		~	\checkmark	line	cages	DY.3	BA.2.76	BA.5.2.8	BA.5.2.6	BA.2.21
				abun	idances	0.696521	0.18806666	0.057470	0.02074663	0.01880
				re	esid	7.214499616		09		344
				cov	erage	99.2372286				
64	XBG-3	BA.2.76	DZ.2	XBG-3			0.075547147204			
		\checkmark	\checkmark	sumn	narized	[('Omicron',	2124)]			
		~	\checkmark	line	cages	DZ.2	BA.2.76	BF.7.8	BA.5.2.49	BA.5.2
				abun	idances	0.710714	0.17746544	0.048016 97	0.028768	274
				re	esid	6.811211485				
	NDC 1	D. 227	D 1 (17.2	cov	erage	98.94951658				
65	ABC-1	BA.2.3.7	B.1.017.2	ABC-1		F20 1	0.674413431160	(17) I. I.	0.2862149379552	
				sumn	narized	[(Omicron',	793),	('Delta',	3584)]	×
		Ň	N	line	rages	BA.2.3.7	AY./1	AAC	B.1.1.529	0.04540
				abun	.dances	0.48059	0.28621494	0.085504	0.06291834	109
				re	esid	17.89729333				
66	XBC-2	BA.2.3.7	AY.36	XBC-2	crage	<i>yy.10923</i> 422				
		~	\checkmark	summ	narized	[('Omicron',	0.604678167568	('Delta',	0.3828893309450	
		~	1	line	cages	BA.2.3.7	7859), AY.36	XAH	955)j XAT	XE
				abun	adances	0.412766	0.38288933	0.126326	0.03975602	0.02582
				re	esid	16.91366773		65		949
				cov	erage	99.8829079				
67	XBC-3	BA.2.3.7	AY.30	XBC-3						
		~	\checkmark	sumn	narized	[('Omicron',	0.053757107887	('Delta',	262)]	
		\checkmark	\checkmark	line	eages	BA.2.3.7	AY.30	XM		
				abun	idances	0.56310596	0.27988335	0.090651		
				re	esid	20.62633746				
(0	VDD 1	TO CLL	D. I	cov	erage	99.65541467				
68	XDD-1	EG.5.1.1	JIN.I	XDD-1		500 L .	0.995041762635			
		N	N	sumn	narized	[('Omicron',	4994)]	DA 2.96		
		\checkmark	\checkmark	line	eages	EG.5.1.1	JN.1	1 1		
				abun	dances	0.63530975	0.242105	0.117627		
				re	esid	17.62939286		01		
				cov	erage	99.72566993				
69	XDD-2	EG.5.1.1	JN.1.1	XDD-2			0 992504072806			
		1		summ	narized	[('Omicron',	8011)]			
		N	V	line	cages	EG.5.1.1	BA.2.86.1	JN.1.1		
				abun	esid	17.53110218	0.219731	0.170211		
				cov	erage	99.72566993				
70	XDD-3	EG.5.1.1	JN.1.3	XDD-3			0.002421245005			
		\checkmark		summ	narized	[('Omicron',	0.992421745996 3304)]			
		\checkmark		line	cages	EG.5.1.1	JN.1	BA.2.86.	JN.10	JN.3
				ahun	dances	0.67941148	0.15006142	0.075057	0.049576	0.03831
				adun	esid	16 78885854	0.10000142	5.075057	0.019570	585
				covi	erage	99.70225151				

Supplementary Table 3. The original genotypes and the recovered genotypes of 3 real samples in routine tests.

Named sample	Detection date	Original sample	Genotypes	single sequencing)	-	Genotypes	(pooled seq	uencing)		
mix-S12	2023/5/24-25	RY1126	EG.5.1.1	XBB.1.9.2.5.1.1	lineages	EG.5.1.1	FL.2.4	EG.5		
		RY1177	EG.5.1.1	XBB.1.9.2.5.1.1	abundances	63.97%	33.70%	1.41%		
		RY1218	FL.2.4	XBB.1.9.1.2.4	resid	2.13444				
					coverage	99.14%				
test-mix1	2023/9/5	2702	FL.15	XBB.1.9.1.15	lineages	FY.3.3	EG.5.1.1	FL.15.2	XBB.1.16.12	XBB.1.16
		2706	XBB.1.16	XBB.1.16	abundances	34.56%	19.60%	16.60%	9.46%	7.07%
		2713	EG.5.1.1	XBB.1.9.2.5.1.1	resid	4.44507				
		2742	FY.3	XBB.1.22.1.3	coverage	99.24%				
test-mix2	2023/9/5	2874	FL.4.5	XBB.1.9.1.4.5	lineages	EG.5.1.1	FL.4.5	JJ.1	EG.5.1.4	
		2896	EG.5.1.4	XBB.1.9.2.5.1.4	abundances	45.84%	28.28%	18.11%	5.49%	
		2928	EG.5.1.1	XBB.1.9.2.5.1.1	resid	4.03265				
		2947	HK.3	XBB.1.9.2.5.1.1.3	coverage	99.24%				